Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer

News provided by

Sep 29, 2014, 07:47 ET

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic.

Anti-infective drugs can act via host defence system or can directly target the causative agent.

The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Infectious Disease Treatment market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include:

Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials)
Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals)
Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs)
Antiparasitic drugs

The report, the Global Infectious Disease Treatment Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Infectious Disease Treatment market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies.

According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients.

Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Application

08. Global Antibacterial Drugs Market

09. Global Antifungal Drugs Market

10. Global Antiviral Drugs Market

11. Global Antiparasitic Drugs Market

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

21. Key Vendor Analysis

22. Other Reports in this Series

Companies Mentioned: